in 34 patients with ventricular tachyarrhythmias the effect of the antiarrhythmic therapy of sotalol ( 160-320 mg p.o . ) in combination with the type-i-b-agent mexiletine ( 600-800 mg p.o . ) or tocainide ( 800-1200 mg p.o . ) was studied by holter monitoring .
C0003195
antiarrhythmic
C0037707
sotalol